Transdermal Delivery of Cannabinoid and Opiate Prodrugs for Pain Treatment
Audra Stinchcomb, Ph.D., Chief Scientific Officer, AllTranz

Plasma and Cerebrospinal Fluid Pharmacokinetic Parameters after Single-Dose Administration of Intravenous, Oral or Rectal Acetaminophen
Mike Royal, MD VP Clinical Development & Medical Affairs, Cadence Pharmaceuticals
Neil Singla, MD, CEO, Lotus Clinical Research

Identification of a Non-opioid Analgesic Candidate VVZ-149, Selective to Three Pain Targets, GlyT2, 5HT2A and P2X3, with Moderate Potency
Pang Min-hee, Ph.D., Senior Researcher, VizoZon, Inc.
Sunyoung Cho, Ph.D., Research Director, VivoZon, Inc.

Analgesic Properties of S-Etifoxine and β-Subunit Selective Modulators of GABAA Receptors
Tim Johnstone, Ph.D., Research Specialist, UC Irvine

BL-1021: A New Chemical Entity for the Treatment of Neuropathic Pain
Yotam Nisemblat, M.Sc., Senior Drug Development Manager, BioLineRx

A New Class of Pain Therapeutics - ddRNAi Gene Constructs
Peter French, Ph.D., Chief Executive Officer, Benitec Limited

High Throughput Automated Behavioral Assessment for Enhanced Translation in Analgesic Drug Discovery
David Lowe, Ph.D., Chief Scientific Officer, PsychoGenics

Comparison of Analgesic Effects of an Allosteric Inhibitor of TrkA to that of an ATP site inhibitor of the pan-Trk axis in a Rodent Model of Inflammatory Pain
Steven Andrews, Ph.D., Associate Director, Drug Discovery, Array Biopharma

Management of Placebo Response Yields Proof of Concept in Randomized Trial of KRN5500 in Patients with Neuropathic Pain and Cancer – What Went Right?
Linda Jett, MSN, RN, Clinical Director of Drug Development, Dara BioSciences